Although our observation was done in a very limited number of patients, our result is much better than expected, because the chance of observing an objective response in four consecutive STS patients treated with DOX is 0.4%.
We observed an overall objective response in 34.3% of patients treated with the combined chemoimmunotherapy which is comparable with earlier trials achieving response rates between 23%to64%4% (Atkins et al, 1994; Atzpodien et al, 1995; Feun et al, 1995; Hoffmann et al, 1998; Johnston et al, 1998; Legha, 1998; Middleton et al, 2000; Pyrhonen et al, 1992; Rosenberg et al, 1999; Thompson et al, 1997).
We observed a 37% objective response rate (four complete and six partial) and 81.5% disease control rate (10 objective responses+12 disease stabilisations).
An attempt is made to characterize and quantify any systematic difference that exists between the mean behavioral patterns of the critical parameters as described by the IRI and those observed, with an objective to improve the IRI prediction capability.
Neither complete response nor partial response was observed for an objective response rate of 0% (Table 4).
Reviewing 440 patients, only four complete and nine partial responses were observed, rendering an objective response rate of 3%% [ 7].
One complete response and 10 partial responses were observed, for an objective response rate of 26.2%95(95 % CI, 12.9 % to 39.5 %).
Only partial responses were observed with an objective response rate of 2.7 and 5.5% in the 3-weekly and weekly arm, respectively (P=0.50).
In this study in a general population sample, we did not observe an association between objective sleep duration and diabetes.
